←Adolescence & Development
Study register · detail Prospektive Kohortenstudie · Adolescence & Development · 1987

Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.

Andréasson et al. ·The Lancet
Harm GRADE Low 1144 citations
Samplen = 45.570 Pat.
Duration15-year follow-up
ControlNon-users
EndpointSchizophrenia incidence
Blindingn.a.
DesignProspektive Kohortenstudie
Key finding

High cannabis use increases the risk of schizophrenia sixfold, independent of other psychiatric disorders and social background.

Summary

Prospective 15-year cohort study (n=45.570 Swedish conscripts); high users (>50 occasions) had RR=6,0 (95% CI 4,0–8,9) for schizophrenia vs. non-users; cannabis confirmed as an independent risk factor after adjustment for other psychiatric disorders and social background.

P
PopulationSwedish conscripts without initial schizophrenia diagnosis, n=45.570
I
InterventionCannabis use (high: >50 occasions; various levels of use)
C
ControlNon-users
O
OutcomeRelative risk for schizophrenia in high users: RR=6,0 (95% CI 4,0–8,9) vs. non-users
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Harm
Citations / year ★★★★★
Authors
Andréasson S, Allebeck P, Engström A, Rydberg U.
DOI 10.1016/s0140-6736(87)92620-1↗
Design: Prospektive Kohortenstudie
Share
Abstract
The association between level of cannabis consumption and development of schizophrenia during a 15-year follow-up was studied in a cohort of 45,570 Swedish conscripts. The relative risk for schizophrenia among high consumers of cannabis (use on more than fifty occasions) was 6.0 (95% confidence interval 4.0-8.9) compared with non-users. Persistence of the association after allowance for other psychiatric illness and social background indicated that cannabis is an independent risk factor for schizophrenia.
Indication
Further studies on Adolescence & Development
All studies →
S Gobbi et al. · 2019 · JAMA Psychiatry
886 citations
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
Clear benefit Meta-Analyse

SR über 11 Studien (n=23.317 Jugendliche); adoleszenter Cannabis-Konsum assoziiert mit erhöhtem Risiko für Depression im jungen Erwachsenenalter (OR=1.37, 95% CI 1.16-1.62, p0.001), Angststörungen (OR=1.18, 95% CI 1.10-1.26, p0.001) und Suizidalität (OR=1.50, 95% CI 1.11-2.03, p0.01).

10.1001/jamapsychiatry.2018.4500 View study →
S Silins et al. · 2014 · The Lancet Psychiatry
438 citations
Young adult sequelae of adolescent cannabis use: an integrative analysis.
Harm IPD-Meta-Analyse (3 Longitudinalstudien)

IPD-Meta-Analyse (N bis 3.765); täglicher Cannabiskonsum vor 17 Jahren: aOR 0,37 (CI 0,20–0,66) für Schulabschluss, 17,95 (CI 9,44–34,12) für Cannabisabhängigkeit, 7,80 (CI 4,46–13,63) für andere illegale Drogen, 6,83 (CI 2,04–22,90) für Suizidversuch; klare Dosis-Wirkung für alle 7 Entwicklungs-Outcomes.

10.1016/s2215-0366(14)70307-4 View study →
A Lowe et al. · 2024 · The American journal of drug and alcohol abuse
23 citations
Cannabis use in adolescents and anxiety symptoms and disorders: a systematic review and meta-analysis.
Clear benefit Meta-Analyse

SR + Meta-Analyse über k=18 Längsschnittstudien (n=33.380) zu adoleszentem Cannabis-Konsum und späteren Angst-Outcomes; Meta-Analyse von k=6 Studien zeigt erhöhtes Risiko für spätere Angststörungen (OR=2.14, 95% CI: 1.37-3.36, p<0.01). Qualitative Synthese von k=12 weiteren Studien: 9 von 12 fanden signifikanten Zusammenhang zwischen adoleszentem Cannabis-Konsum und späteren Angstsymptomen.

10.1080/00952990.2023.2299922 View study →

The impediment to action advances action. — Marcus Aurelius